2024
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient ageModulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury
Singh S, Budiman T, Redmond D, Gupta V. Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatology Communications 2024, 8: e0368. PMID: 38251878, PMCID: PMC10805418, DOI: 10.1097/hc9.0000000000000368.Peer-Reviewed Original ResearchConceptsT-box transcription factorTranscription factorsMesenchymal gene expressionSignaling effectorsGene expressionGli transcription factorsGene transcription programUpregulation of TBX2Gain of functionSingle-cell sequencingExtrahepatic bile ductCellular identityTranscriptome analysisTranscriptional programsReceptor-ligand analysisMyofibroblast transdifferentiationIn vivo approachesB-cateninT-boxSignaling pathwayBile ductTbx3 expressionTbx3Primary sclerosing cholangitisBile duct ligation
2023
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.Peer-Reviewed Original ResearchStatin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors
Juarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh S, Dong V, Roberts A, Leverson J, Jalaluddin M, Liu Z, Bueno O, Boise L, Fruman D. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications 2023, 3: 2497-2509. PMID: 37956312, PMCID: PMC10704957, DOI: 10.1158/2767-9764.crc-23-0350.Peer-Reviewed Original ResearchProphylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.Peer-Reviewed Original ResearchCytokine release syndromeGrade 3 cytokine release syndromeSeverity of CRSB-cell maturation antigenProphylactic cohortRelease syndromeMedian durationRRMM patientsAdditional patientsREMS programT-cell engaging therapiesGrade 1Institutional guidelinesDose of steroidsFirst full doseDays of dischargeEmory University HospitalCD38 monoclonal antibodyUsage of steroidsCellular Therapy criteriaDose delaysNeurotoxicity syndromeOutpatient administrationT cell surfaceTocilizumab groupA Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.Peer-Reviewed Original ResearchProgression-free survivalArm BPeripheral neuropathyInduction therapyPrimary endpointOverall survivalAutologous stem cell transplantGrade 3/4 peripheral neuropathyRandomized phase 2 studyTransplant-eligible myeloma patientsRandomized phase II studySecondary primary malignanciesTransplant-eligible patientsTransplant-ineligible patientsAdverse event profilePhase 2 studyPhase II studyStem cell transplantWinship Cancer InstituteInhibitor combination therapyStem cell collectionRegular clinical practiceHigh response rateMultiple myeloma studyMedian followComparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristicsEfficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.Peer-Reviewed Original ResearchStandard-risk patientsVGPR ratesRisk patientsPart of inductionInduction therapyMyeloma patientsNDMM patientsInternational Myeloma Working Group Uniform Response CriteriaStage 3 patientsCombination of lenalidomideHigh-risk patientsPhase 3 studyCohort of patientsUniform response criteriaDistinct clinical presentationsFree light chainsInstitutional review boardLenalidomide maintenanceMedian OSMedian PFSRVD inductionLast followClinical characteristicsOverall survivalPatient characteristicsMachine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears
Lewis J, Shebelut C, Attieh M, Horwath M, Khanna A, Al-Rusan O, Ponnatt T, Smith G, Gutman D, Gupta V, Aljudi A, Cooper L, Jaye D. Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears. Blood 2023, 142: 7158. DOI: 10.1182/blood-2023-190686.Peer-Reviewed Original ResearchPlasma cell neoplasmsMolecular genetic subtypesBone marrow aspirate smearsMarrow aspirate smearsCell neoplasmsPlasma cellsAspirate smearsMultiple myelomaGenetic subtypesRisk stratificationBone marrow biopsy samplesCurrent prognostic systemsRisk stratification toolCommon hematologic malignancyPlasma cell morphologyMultiple myeloma casesSpecific morphologic featuresSubset of casesRecurrent genetic abnormalitiesLow-resource settingsBiologic subtypeStratification toolAggressive diseaseScanned whole slide imagesHematologic malignanciesHeterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal
Singh S, Lian Q, Budiman T, Taketo M, Simons B, Gupta V. Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal. Developmental Cell 2023, 58: 2732-2745.e5. PMID: 37909044, PMCID: PMC10842076, DOI: 10.1016/j.devcel.2023.10.004.Peer-Reviewed Original Research
2021
Cell and Tissue Therapy for the Treatment of Chronic Liver Disease
Bram Y, Nguyen DT, Gupta V, Park J, Richardson C, Chandar V, Schwartz RE. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. Annual Review Of Biomedical Engineering 2021, 23: 1-30. PMID: 33974812, PMCID: PMC8864721, DOI: 10.1146/annurev-bioeng-112619-044026.Peer-Reviewed Original ResearchConceptsLiver diseaseLiver transplantationOrgan transplantationNonalcoholic fatty liver diseaseTissue-based therapiesChronic liver diseaseFatty liver diseaseSolid organ transplantationCommon solid organ transplantationImportant clinical problemCause of deathLiver failureRisk factorsClinical problemAvailable organsTransplantationTherapyDiseaseGold standardRegenerative therapyTissue therapyTreatmentCellsSteatohepatitisMorbidity
2020
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids
Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27: 125-136.e7. PMID: 32579880, PMCID: PMC7303620, DOI: 10.1016/j.stem.2020.06.015.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionHuman disease-relevant cellsSARS-CoV-2 tropismCOVID-19 pathophysiologyExpression of chemokinesRecent clinical studiesHuman pancreatic beta cellsCOVID-19SARS-CoV-2Pancreatic beta cellsLiver organoidsPancreatic endocrine cellsRespiratory failureDopaminergic neuronsClinical studiesPrimary human isletsVirus infectionAutopsy samplesBeta cellsHuman isletsEndocrine cellsOrgan systemsInfectionCholangiocyte organoidsDisease-relevant cellsHedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells
Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.Peer-Reviewed Original ResearchConceptsCholestatic injuryStellate cellsLiver tissueStromal cellsLiver diseaseBile ductBiliary treePortal tractsMesenchymal cellsPrimary sclerosing cholangitisAlcoholic liver diseaseEpithelial cellsMyofibroblast phenotypeQuantitative reverse transcription polymerase chain reactionBile duct ligationReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionCanals of HeringControl liver tissueHedgehog signalingSclerosing cholangitisHepatic injuryHepatocellular injuryNonalcoholic steatohepatitisPortal fibroblasts
2019
Hepatology Highlights
Amir M, Vora RS, Tafesh ZH, Jesudian A, Gupta V, Schwartz RE, Russo N, Danford CJ, Lau DTY, Brown RS, Jalan-Sakrikar N, Maiers JL, Sharma R, Fortune BE, Hilscher M, Aseem SO. Hepatology Highlights. Hepatology 2019, 70: 1497-1499. PMID: 31661168, DOI: 10.1002/hep.30995.Peer-Reviewed Original ResearchHepatology Highlights
Suri JS, Ezaz G, Lau DTY, Kulai TB, Malhi H, Tafesh ZH, Fortune B, Rosenblatt R, Brown RS, Pisa JF, Russo N, Hirsova P, Schwartz RE, Obaidullah Aseem S, Jalan-Sakrikar N, Gupta V. Hepatology Highlights. Hepatology 2019, 69: 2311-2314. PMID: 31141204, DOI: 10.1002/hep.30775.Peer-Reviewed Original ResearchHepatology Highlights
Mousa O, Malhi H, Schwartz RE, Kulai TB, Trivedi HD, Lau DTY, Shen NT, Brown RS, Hirsova P, Xu X, Nicholls HT, Pisa JF, Tafesh ZH, Fortune BE, Gupta V, Kostallari E, Russo N, Jesudian AB. Hepatology Highlights. Hepatology 2019, 69: 927-930. PMID: 30811657, DOI: 10.1002/hep.30569.Peer-Reviewed Original ResearchHepatology Highlights
Russo N, Brown RS, Shah SL, Krisko TI, Krumm CS, Nicholls HT, Mousa O, Malhi H, Schwartz RE, Lominadze Z, Rosenblatt R, Fortune BE, Pisa JF, Jesudian AB, Gupta V, Tafesh ZH. Hepatology Highlights. Hepatology 2019, 69: 469-472. PMID: 30695118, DOI: 10.1002/hep.30511.Peer-Reviewed Original ResearchHepatology Highlights
Russo N, Jesudian A, Shen NT, Brown RS, Sugiyama A, Nicholls HT, Pisa JF, Krisko TI, Rosenblatt R, Tafesh ZH, Fortune BE, Mousa O, Malhi H, Schwartz RE, Gupta V, Kulai TB, Malhi H. Hepatology Highlights. Hepatology 2019, 69: 1-4. PMID: 30618107, DOI: 10.1002/hep.30480.Peer-Reviewed Original Research
2015
Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysis
Gupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, Ananthakrishnan AN. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysis. Alimentary Pharmacology & Therapeutics 2015, 43: 52-60. PMID: 26541937, PMCID: PMC4673010, DOI: 10.1111/apt.13454.Peer-Reviewed Original ResearchConceptsLength of stayMedical rescue therapyInflammatory bowel diseaseRescue therapyIntravenous steroidsInflammatory bowel disease exacerbationLong-term clinical outcomesGreater LOSSurgical rescue therapyRetrospective cohort studyLong-term outcomesAddition of antibioticsOutcomes of interestSignificant long-term benefitAdjuvant antibioticsIBD exacerbationIBD patientsDisease exacerbationClinical improvementCohort studyBowel diseaseUlcerative colitisClinical outcomesCrohn's diseaseAdjuvant use
2013
Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration
Fang Y, Gupta V, Karra R, Holdway JE, Kikuchi K, Poss KD. Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 13416-13421. PMID: 23901114, PMCID: PMC3746860, DOI: 10.1073/pnas.1309810110.Peer-Reviewed Original ResearchConceptsHeart regenerationSTAT3 inhibitionCertain lower vertebratesZebrafish heart regenerationRibosome affinity purificationTranslational profilingProgram essentialLower vertebratesAffinity purificationPathway membersSTAT3-dependent mannerZebrafish cardiomyocytesCardiomyocyte proliferationAnimal growthInjury-induced proliferationDynamic inductionProliferationCardiomyocytesInjury responseRegenerationRln3aVertebratesCardiogenesisRNAInhibition